Blood Components
Available from Blood Center
| Component/ Product |
Composition |
Approximate
Volume * |
Indication/Qualifiers |
| Red Blood Cell Products |
| Red blood cells |
RBC; reduced plasma |
330 mL |
Increase red cell
mass |
| Washed RBC |
RBC; minimal plasma |
250 mL |
Increase red cell
mass; reduce febrile or allergic reactions due to cytokines or plasma
proteins |
| Frozen, thawed, deglycerolized
RBC |
RBC; minimal WBC
and platelets; no plasma |
180 mL |
Increase red cell
mass; reduce febrile transfusion reactions; reduce sensitization to
leukocyte antigens; minimize allergic transfusion reactions; rare
or autologous blood storage |
| Autologous blood |
Autologous RBC or
whole blood |
180-500 mL |
Increase red cell
mass with predeposited autologous blood |
| Platelet Products |
| Platelets by apheresis |
Platelets; plasma
(>3 x 1011 platelets/unit); few RBC |
250 mL |
Prevention of bleeding
due to thrombocytopenia or thrombocytopathy (5-day shelf-life). May
be HLA matched, if specified |
| Pooled platelets
- platelet concentrates from 4 units of blood |
Platelets (average
of 9x1010 platelets/unit); plasma; few RBC |
200 mL |
Prevention of bleeding
due to thrombocytopenia or thrombocytopathy (shelf life 5 days for
unpooled units, 4 hours after pooling). |
| Plasma
Products |
| Fresh frozen plasma |
Plasma; all coagulation
factors; complement (no cellular components |
250 mL |
Treatment of some
coagulation disorders |
| Pooled cryoprecipitate
- from 4 units of blood |
Fibrinogen; factors
VIII and XIII; von Willebrand factor; fibronectin |
60 mL |
Deficiency of factor
XIII or fibrinogen; treatment of von Willebrand disease |
| Rh immune globulin |
IM IgG anti-D |
1 mL |
Prevention of hemolytic
disease of the newborn due to D antigen |
| WinRho |
IV IgG anti-D |
2.5 mL |
Treatment of ITP,
suppression of Rh immunization |
| *
Note: Smaller aliquots may be prepared for infants/children |
| Coagulation
Factors Available |
VIII
Recombinatea |
VIII
Hemofil-Mb
Humate-P (vWF) |
IX
Benefixa |
Activated
Feiba-VH
NovoSevena |
| a.
Recombinant b. Affinity-purified with monoclonal antibody |
Special Requirements
1. Leukocyte reduced blood components contain less than 5 x 106 WBC per
unit and may reduce febrile transfusion reactions; reduce sensitization
to leukocyte antigens.
2. A low risk of CMV in cellular blood components will be achieved by
leukocyte reduction unless a CMV seronegative product is specified. CMV
low risk cellular blood components are indicated for: certain transplant
recipients; intrauterine transfusions; exchange transfusions in neonates.
Neonates with birth weight less than 1200g whose mother's CMV status is
negative or unknown should receive CMV low risk blood products for the
first four months of life.
3. Stem Cell Transplant - Pre-transplant: Potential transplant candidates
who are CMV-negative or not yet CMV tested should receive CMV low risk
cellular blood components and should be tested as soon as possible. Post-transplant:
CMV-negative bone marrow transplant recipients who receive CMV-negative
donor stem cells should receive CMV low risk cellular blood components
for four months post-transplant.
4. Irradiated blood components are indicated for: stem cell transplant
recipients starting two weeks prior to transplant and continuing indefinitely;
intrauterine transfusions and any neonatal transfusions following them;
pediatric patients with congenital or acquired immunodeficiencies; directed
donations from blood relatives. To accomplish the latter, all directed
donations and all single donor platelets are routinely irradiated in the
Blood Center.
5. HLA matched platelets require prearrangement with the Blood Center
(2-5920) and HLA typing and HLA antibody screening by the HLA lab (2-8393).
|
